#USA #Delft #AdJane #Nm-nOMV #Respiratory Vaccines

AdJane's Innovative Approach to Respiratory Vaccines

AdJane Biosciences has recently taken a significant step in the realm of vaccine development with the introduction of a mucosal booster strategy aimed at enhancing respiratory vaccines. This new initiative leverages the company’s Neisseria meningitidis native Outer Membrane Vesicle (Nm-nOMV) technology, which has been clinically validated to promote both systemic and mucosal immunity.

The Need for Mucosal Immunity

Current intramuscular respiratory vaccines have proven effective in inducing strong systemic immunity that protects against severe diseases. However, they often fall short in generating adequate immunity at the mucosal surfaces where respiratory pathogens initially invade the body. By adding a mucosal component to existing vaccination frameworks, AdJane aims to fill this gap, addressing the growing body of evidence suggesting that mucosal immunity, particularly immunoglobulin A (IgA), plays a crucial role in reducing pathogen transmission.

A New White Paper Publication

To illuminate their strategy, AdJane has published a detailed White Paper entitled Boosting mRNA Mucosal Immunity and a Platform Beyond It. This document outlines the potential of their Nm-nOMV platform to complement established intramuscular vaccines by fostering immune responses right at the respiratory mucosa, where infections commonly begin. The company's mission aligns with public health objectives to mitigate infection rates while also reducing severe disease outcomes.

The Prime-Boost Strategy

AdJane's approach adopts a heterologous prime-boost strategy, beginning with systemic priming through established intramuscular vaccines, followed by an intranasal booster. This novel add-on aims to induce a complementary immune response at the site of infection, thereby enhancing existing vaccination regimens.

"Respiratory vaccine innovation can build upon what already works. We want to add an intranasal Nm-nOMV booster to established intramuscular vaccines to stimulate immunity at the infection point," stated Anita Gashi, CEO of AdJane. This perspective underscores the company's strategy to harness recognized vaccination methodologies while fostering innovation through tailored mucosal boosters.

Leveraging Existing Frameworks

The design of AdJane’s booster strategy seeks to integrate seamlessly with current respiratory vaccine frameworks. The company believes this dual approach can pave new pathways for advancements in the field. Their robust intellectual property portfolio surrounds the Nm-nOMV platform, encompassing protections related to manufacturing processes, mucosal dosing, and variant vaccine applications.

Initial Clinical Insights

Supporting their concept, AdJane's recent Phase I study has shown promising results. In a subset of participants who previously received Pfizer or Moderna COVID-19 mRNA vaccines, the subsequent intranasal administration of an Nm-nOMV vaccine displaying the SARS-CoV-2 Spike protein was well tolerated and led to significant IgA responses in the nasal mucosa. These findings represent an initial human validation of the mucosal booster hypothesis and set the stage for further exploration.

Expanding the Application Spectrum

The White Paper also discusses the far-reaching implications of this booster strategy. The limitations in mucosal immunity are not exclusive to mRNA vaccines; many intramuscular respiratory vaccination approaches exhibit similar gaps. Following further research, AdJane envisions potential applications across various viruses, including COVID-19, influenza, RSV, and even for preparing against future pandemics.

Future Directions

AdJane Biosciences is excited about the broader implications of the Nm-nOMV platform. As the company continues to innovate, they are committed to advancing their technology across various vaccine modalities and infectious disease indications. The integration of systemic priming and proprietary mucosal boosting stands to significantly enhance the efficacy of respiratory vaccines.

For further insights and detailed information, visit the official website at AdJane Biosciences.